CD274 and neoplasm: The tumor mutation burden (TMB), neoantigen load and clonality, copy number alterations (CNA), microsatellite instability (MSI) status, tumor microenvironment (TME), especially T cell inflammation, PD-L1 expression, and mutations in specific genes are now deemed to be predictive markers for immunotherapy in aGC patients.